MX2021011107A - Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infeccion por vhb o enfermedades inducidas por vhb. - Google Patents

Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infeccion por vhb o enfermedades inducidas por vhb.

Info

Publication number
MX2021011107A
MX2021011107A MX2021011107A MX2021011107A MX2021011107A MX 2021011107 A MX2021011107 A MX 2021011107A MX 2021011107 A MX2021011107 A MX 2021011107A MX 2021011107 A MX2021011107 A MX 2021011107A MX 2021011107 A MX2021011107 A MX 2021011107A
Authority
MX
Mexico
Prior art keywords
hbv
treatment
fused ring
induced diseases
pyrimidone derivatives
Prior art date
Application number
MX2021011107A
Other languages
English (en)
Inventor
Edgar Jacoby
Bart Rudolf Romanie Kesteleyn
Tim Hugo Maria Jonckers
Pierre Jean- Marie Bernard RABOISSON
Grosse Sandrine Céline
Serge Maria Aloysius Pieters
Stefaan Julien Last
Abdellah Tahri
Koen Vandyck
Wim Gaston Verschueren
Lili Hu
Jan Martin Berke
Lamenca Carolina Martinez
Meng- Yang HSIAO
Mathieu Perrier
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MX2021011107A publication Critical patent/MX2021011107A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud se refiere a compuestos de acuerdo con la fórmula (I), composiciones farmacéuticas que comprenden al menos uno de dichos compuestos, su uso como medicamento y su uso en el tratamiento de la infección crónica por el virus de la hepatitis B (VHB); la divulgación se refiere además a métodos para preparar compuestos de acuerdo con la fórmula (I).
MX2021011107A 2019-03-14 2020-03-13 Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infeccion por vhb o enfermedades inducidas por vhb. MX2021011107A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19162954 2019-03-14
PCT/EP2020/056884 WO2020182990A1 (en) 2019-03-14 2020-03-13 Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases

Publications (1)

Publication Number Publication Date
MX2021011107A true MX2021011107A (es) 2022-01-19

Family

ID=65817822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011107A MX2021011107A (es) 2019-03-14 2020-03-13 Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infeccion por vhb o enfermedades inducidas por vhb.

Country Status (23)

Country Link
US (1) US20230091047A1 (es)
EP (1) EP3938362A1 (es)
JP (1) JP2022524456A (es)
KR (1) KR20210139319A (es)
CN (1) CN113710667A (es)
AR (1) AR118358A1 (es)
AU (1) AU2020235270A1 (es)
BR (1) BR112021017415A2 (es)
CA (1) CA3132531A1 (es)
CL (1) CL2021002390A1 (es)
CO (1) CO2021011295A2 (es)
CR (1) CR20210482A (es)
DO (1) DOP2021000185A (es)
EA (1) EA202192512A1 (es)
EC (1) ECSP21067189A (es)
IL (1) IL286210A (es)
JO (1) JOP20210249A1 (es)
MA (1) MA55286A (es)
MX (1) MX2021011107A (es)
PE (1) PE20212325A1 (es)
SG (1) SG11202109575UA (es)
TW (1) TW202100524A (es)
WO (1) WO2020182990A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202227435A (zh) * 2020-09-11 2022-07-16 愛爾蘭商健生科學愛爾蘭無限公司 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之稠合環嘧啶酮衍生物
CN116724038A (zh) * 2020-10-21 2023-09-08 安力高医药股份有限公司 双环化合物
WO2022266193A1 (en) * 2021-06-18 2022-12-22 Aligos Therapeutics, Inc. Bicyclic compounds
US20230374008A1 (en) * 2022-04-20 2023-11-23 Aligos Therapeutics, Inc. Bicyclic compounds
WO2023205653A1 (en) * 2022-04-20 2023-10-26 Aligos Therapeutics, Inc. Bicyclic compounds
WO2024015425A1 (en) 2022-07-14 2024-01-18 Fmc Corporation Herbicidal benzoxazines
US20240150351A1 (en) * 2022-09-30 2024-05-09 Aligos Therapeutics, Inc. Bicyclic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078719A4 (en) 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION
JP2010524940A (ja) * 2007-04-20 2010-07-22 シェーリング コーポレイション ピリミジノン誘導体およびそれらの使用方法
CN101854597B (zh) 2009-04-03 2015-06-03 中兴通讯股份有限公司 大消息模式融合ip消息传输方法及系统
WO2011111880A1 (ko) * 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
JP2012126698A (ja) * 2010-12-17 2012-07-05 Tsutomu Takeuchi テトラヒドロピリドピリミジン誘導体を有効成分とするｂａｆｆの結合阻害剤
JP6713465B2 (ja) * 2014-12-30 2020-06-24 ノヴィラ・セラピューティクス・インコーポレイテッド Ｂ型肝炎感染症治療のための誘導体及び方法
CN110088104B (zh) * 2016-11-03 2022-04-12 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的四氢吡啶并嘧啶化合物

Also Published As

Publication number Publication date
CL2021002390A1 (es) 2022-04-22
EP3938362A1 (en) 2022-01-19
SG11202109575UA (en) 2021-09-29
CN113710667A (zh) 2021-11-26
AU2020235270A1 (en) 2021-08-12
ECSP21067189A (es) 2021-11-18
JP2022524456A (ja) 2022-05-02
IL286210A (en) 2021-10-31
CR20210482A (es) 2021-11-09
JOP20210249A1 (ar) 2023-01-30
CA3132531A1 (en) 2020-09-17
DOP2021000185A (es) 2022-01-16
MA55286A (fr) 2022-01-19
PE20212325A1 (es) 2021-12-14
AR118358A1 (es) 2021-09-29
US20230091047A1 (en) 2023-03-23
BR112021017415A2 (pt) 2022-02-01
TW202100524A (zh) 2021-01-01
KR20210139319A (ko) 2021-11-22
WO2020182990A1 (en) 2020-09-17
CO2021011295A2 (es) 2021-09-20
EA202192512A1 (ru) 2022-02-16

Similar Documents

Publication Publication Date Title
CR20210482A (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
MX2018015315A (es) Agentes antivirales contra la hepatitis b.
PH12018550148A1 (en) Hepatitis b antiviral agents
ZA202107015B (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
PH12021551116A1 (en) Functionalized heterocycles as antiviral agents
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
PH12020550065A1 (en) Hepatitis b antiviral agents
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PH12019550113A1 (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
TN2015000293A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
MX2021003253A (es) Heterociclos funcionalizados como agentes antivirales.
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
PH12021550632A1 (en) Monomer and multimeric anti-hbv agents
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
MX2022009871A (es) Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih).
IN2011CH03893A (es)
MX2021013594A (es) Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
MX2021014576A (es) Derivados heterociclicos condensados como agentes antivirales.
EA201892732A1 (ru) Противовирусные средства для лечения гепатита в
EA201892004A1 (ru) Противовирусные средства для лечения гепатита b
MX2019011173A (es) Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c.
MX2019015480A (es) Preparacion medicinal combinada para tratar infecciones virales.